Hong Kong drug and medical device registrations are increasingly in demand because of market trends and opening of regulatory pathways to China’s Greater Bay Area, which has a population larger than the UK.
Join the Cisema team for a brief recap of latest updates about Hong Kong registration of drugs and listing of medical devices & IVDs, as well as latest relevant GBA policy updates about accelerated regulatory pathways for sale of healthcare products into one of mainland China’s wealthiest regions.
Date: Tuesday 25 April 2023
Time: 9:00am-9:30am CET
Presenter: Hamish King and Jacky Li
The 30 minutes webinar will cover the following topics:
– Hong Kong registration of pharmaceutical products
– Hong Kong listing of medical device & IVDs
– Trend in approvals
– Latest updates for Greater Bay Area approvals and trends
Sign up for the webinar even if you are in a different time zone, a replay will always be available at a time convenient for you.
The regulatory system for medical devices in unique in Hong Kong, the MDACS (Medical Device Administrative Control System). Unlike the NMPA registration in China, the listing of medical devices in Hong Kong is currently voluntary. However, pharmaceutical products must be registered with the Pharmacy and Poisons Board of Hong Kong before they can be sold, offered for sale, distributed or possessed for the purposes of sale, distribution or other use. From pre-market review to post-market approval, we offer legal representation to support manufacturers with applications for drug registration and medical device listing in Hong Kong. Feel free to reach out to us if you have any Hong Kong regulatory affair enquiries.